My thought is and still PH want to get all the IP to a development stage where BP will buy everything to maximise the value for all the IP. That's why LC mentioned IMU 2.0, they don't want to take any product to commercialisation as Ph3 clinical trial is way too expensive unless the IP goes down the registrational clinical trial path but then this will also be more attractive for a T/O.
IMU Price at posting:
3.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)